23 May 2013
Keywords: ph, iii, trovax, data, renal, cancer, expected
Article | 25 February 2008
UK-based gene medicine firm Oxford BioMedica says that the independent Data Safety Monitoring Board for the Phase III TRIST study ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
25 February 2008
22 May 2013
© 2013 thepharmaletter.com